IMVIONIX Inc., a privately held biotechnology company focused on retinal therapies, announced on November 10, 2026, that it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis. This transaction marks the official commercial launch of IMVIONIX as a commercial-stage ophthalmology enterprise.
Under the terms of the agreement, IMVIONIX will assume the role of marketing authorization holder for BEOVU in the U.S. and Canadian markets. The financial terms of the agreement were not disclosed. BEOVU is approved in both countries for treating Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), which are described as two primary causes of irreversible vision loss.
Rick Eiswirth, Founder and Chief Executive Officer of IMVIONIX, commented that the company was established to provide dedicated focus and reach for proven retinal therapies so that physicians and patients can further benefit. IMVIONIX was founded in 2025 by former executive leaders of Alimera Sciences, Inc. — including Rick Eiswirth, Jason Werner, Todd Wood, and Elliot Maltz — in partnership with Caligan Partners LP and Velan Capital. The founding executives bring a combined sixty years of expertise in ophthalmology and prior experience building ophthalmology brands.
The acquisition of U.S. and Canadian rights to BEOVU was supported by Caligan Partners LP and its investors. BEOVU is administered via intravitreal injection as a humanized single-chain antibody fragment (scFv) VEGF inhibitor. Important safety information for BEOVU highlights risks including endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion (typically alongside intraocular inflammation), increases in intraocular pressure, and potential arterial thromboembolic events.
